RT Journal Article
SR Electronic
T1 Chemotherapy with mitomycin c, ifosfamide, and cisplatin for recurrent or persistent cervical cancer
JF International Journal of Gynecologic Cancer
JO Int J Gynecol Cancer
FD BMJ Publishing Group Ltd
SP 1152
OP 1156
DO 10.1136/ijgc-00009577-200605000-00031
VO 16
IS 3
A1 K. Serkies
A1 J. Jassem
A1 R. Dziadziuszko
YR 2006
UL http://ijgc.bmj.com/content/16/3/1152.abstract
AB The efficacy and toxicity of mitomycin C (MMC), ifosfamide, and cisplatin in cervical cancer were evaluated. Between January 1997 and August 2003, 46 patients with locally recurrent, persistent, or disseminated cervical cancer were treated with MMC 6 mg/m2, ifosfamide 3 g/m2, and cisplatin 50 mg/m2 (MIC regimen) repeated every 3 weeks (maximum six cycles). In eight patients (17%), the tumor involved the pelvis alone, in 11 (24%) the pelvis and extrapelvic sites, and 27 (59%) had only distant lesions. A total of 213 MIC cycles were administered (median six cycles per patient). Of the 44 evaluable patients, the overall response rate was 34% (9% complete and 25% partial responses). Median progression-free interval was 6 months (95% confidence interval [CI], 4–7 months), and overall survival was 10 months (95% CI, 6–14 months). Objective response was obtained in two patients (11%) with pelvic relapse within previously irradiated area and in 13 (50%) of those with extrapelvic lesions (P = 0.01). Leukopenia was seen in 59% of patients (grade 3 in 9%). Nonhematologic side effects were mild and relatively infrequent. In conclusion, MIC regimen provides satisfactory efficacy with acceptable toxicity in advanced cervical cancer patients. Better response is seen in lesions outside of the previously irradiated area.